Rapamycin, a natural compound, has shown anti-aging and health benefits in various researches. Consequently, the popularity and demand for rapamycin supplements have surged significantly in the ...

This study determined whether pharmacological inhibition of the mammalian target of rapamycin (mTOR), a key inhibitor of autophagy, has disease-modifying activity in experimental osteoarthritis.

Researchers say study findings have important implications for our understanding of the pathogenesis of obesity and potential therapeutic applications.

However, no other inflammasome components, nor mitochondrial mass, were affected. The mTOR inhibitor rapamycin restored pro-IL-1β protein levels as well as LPS/ATP-induced IL-1β release from serum ...

This manuscript presents valuable findings showing that rapamycin directly activates the cool-sensing ion channel, TRPM8, acting through a different binding site than other small-molecule cooling ...

In this valuable study, the authors found that the macrolide drug rapamycin, which is an important pharmacological tool in the clinic and the research lab, is less specific than previously thought.

Biodexa Pharmaceuticals (BDRX) is making progress in readying the launch of a phase 3 trial for eRapa, its proprietary encapsulated form of ...

Target Indications Include Microcystic Lymphatic Malformations, Venous Malformations and AngiofibromasProprietary Invisicare Delivery Technology ...

With another approach, researchers at Columbia University have been investigating the use of the immunosuppressant drug rapamycin, which is typically used to prevent organ transplant rejection, in ...

17/391.495 titled “Oral Rapamycin Nanoparticle Preparations and Use” which was exclusively licensed to Biodexa by Rapamycin Holdings, Inc. d/b/a Emtora Biosciences, along with other patents ...

A transformative study has uncovered the pivotal role of the protein Naked cuticle homolog 2 (NKD2) in regulating the differentiation of bone-forming osteoblasts and bone-resorbing osteoclasts.